It has to be underlined that several reports indicate that PSA dosage might not represent a reliable approach for monitoring the response to treatment, since it may present a transitory increase after the first cycle of 223Ra-therapy, in relation to the so-called “PSA flare” due to the release of PSA from tumor cell lysis [21]. Here, KLK3 is linked to neoplasm.